ROMAN STEIKA
Prescription History 1134860323
Student in an Organized Health Care Education/Training Program in Sayre, PA

NPI Status: Active since April 05, 2022

Contact Information

1 GUTHRIE SQ
SAYRE, PA
ZIP 18840
Phone: (570) 888-6666

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ROMAN STEIKA, an active Student in an Organized Health Care Education/Training Program specialist practicing in Sayre, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 318 documented patient claims. Among these therapy options, the most frequently utilized medication is Oxycodone Hcl, which accounts for 111 claims alone.

Medication Index

No matching medications currently found on file.

Celecoxib

Generic Formulation: CelecoxibSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 54
30-Day Fills 56.0
Days Supply 1,675
PA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills56.6
Peer Average Days Supply1,650
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 54.3% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $623.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.55

State Avg Cost Per Claim

$51.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

Therapeutic Applications

This medication is a nonsteroidal anti-inflammatory drug (NSAID), specifically a COX-2 inhibitor, which relieves pain and swelling (inflammation). It is used to treat arthritis, acute pain, and menstrual pain and discomfort. The pain and swelling relief provided by this medication helps you perform more of your normal daily activities. If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section. This drug works by blocking the enzyme in your body that makes prostaglandins. Decreasing prostaglandins helps to reduce pain and swelling.

Cyclobenzaprine Hcl

Generic Formulation: Cyclobenzaprine HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 43
30-Day Fills 43.0
Days Supply 600
PA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills38.9
Peer Average Days Supply963
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.3% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $259.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.04

State Avg Cost Per Claim

$15.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Cyclobenzaprine is used short-term to treat muscle spasms. It is usually used along with rest and physical therapy. It works by helping to relax the muscles. This medication is not recommended for use in older adults because they may be at greater risk for side effects while using this drug. Ask the doctor or pharmacist for details.

Gabapentin

Generic Formulation: GabapentinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 110
30-Day Fills 110.0
Days Supply 3,275
PA State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills141.8
Peer Average Days Supply4,057
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $423.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.85

State Avg Cost Per Claim

$21.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 111
30-Day Fills 111.0
Days Supply 745
PA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills54.4
Peer Average Days Supply1,033
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 105.6% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $531.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.79

State Avg Cost Per Claim

$22.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ROMAN STEIKA provides transparency into local medical care patterns within Sayre, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.